Search

Your search keyword '"Psoriatic arthritis -- Research"' showing total 10 results
Start Over Descriptor "Psoriatic arthritis -- Research" Journal plus company updates
10 results on '"Psoriatic arthritis -- Research"'

1. MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody(r) sonelokimab in active psoriatic arthritis

Subjects
Psoriatic arthritis -- Research, Medical research, Medicine, Experimental, Clinical trials -- Research, Adalimumab -- Research, General interest, News, opinion and commentary
Abstract

ZUG, Switzerland: MoonLake Immunotherapeutics AG has issued the following news release: MoonLake Immunotherapeutics AG (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today [...]

Published
2022

2. New Phase 3 Data Show First-in-Class TREMFYA(r) (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years

Subjects
Johnson & Johnson -- Product development, Psoriatic arthritis -- Research, Skin -- Research, Adults -- Research, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary, American College of Rheumatology, Tremfya (Medication) -- Research -- Product development
Abstract

New Brunswick, New Jersey: Johnson & Johnson has issued the following press release: The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2a [...]

Published
2021

3. RINVOQ (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Study in Psoriatic Arthritis

Subjects
Clinical trials, Medical research, Psoriatic arthritis -- Research, Adalimumab -- Research -- Product development, Arthritis, Psoriasis, Diseases, General interest, News, opinion and commentary
Abstract

NORTH CHICAGO: AbbVie has issued the following press release: AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-PsA 1 clinical trial. [...]

Published
2020

4. Lilly Presents Positive Results for Taltz(r) (ixekizumab) vs. Humira(r) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology

Subjects
Eli Lilly and Co., Ixekizumab -- Research, Pharmaceutical industry, Psoriatic arthritis -- Research, Adalimumab -- Research, Arthritis, General interest, News, opinion and commentary, Taltz (Medication), Humira (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) announced today that the company will present positive findings from the Phase 3b/4 [...]

Published
2019

5. Lilly Presents Positive Results for Taltz (ixekizumab) vs. Humira (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology

Subjects
Eli Lilly and Co., Ixekizumab -- Research, Pharmaceutical industry, Psoriatic arthritis -- Research, Adalimumab -- Research, Arthritis, General interest, News, opinion and commentary, Taltz (Medication), Humira (Medication)
Abstract

Indianapolis: Eli Lilly and Company has issued the following press release: Eli Lilly and Company (NYSE: LLY) announced today that the company will present positive findings from the Phase 3b/4 [...]

Published
2019

6. Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain

Subjects
Novartis AG, Interleukins, Medical research, Pharmaceutical industry, Psoriatic arthritis -- Research, General interest, News, opinion and commentary, American College of Rheumatology, Cosentyx (Medication), Humira (Medication)
Abstract

Zurich: Novartis AG has issued the following press release: Novartis announced today new data showing Cosentyx(r) (secukinumab) delivers sustained improvements in the signs and symptoms of psoriatic arthritis (PsA) over [...]

Published
2016

7. Data on Early Onset of Efficacy for Oral OTEZLA (apremilast) in Active Psoriatic Arthritis Presented at American College of Rheumatology

Subjects
Celgene Corp., Pharmaceutical industry, Psoriatic arthritis -- Research, General interest, News, opinion and commentary, Otezla (Medication)
Abstract

Summit: Celgene Corporation has issued the following news release: Celgene Corporation (NASDAQ: CELG) today announced findings from the ACTIVE phase 3b clinical trial of OTEZLA(r) (apremilast), the Company's oral, selective [...]

Published
2016

8. Data on Early Onset of Efficacy for Oral OTEZLA(r) (apremilast) in Active Psoriatic Arthritis Presented at American College of Rheumatology

Subjects
Celgene Corp., Pharmaceutical industry, Psoriatic arthritis -- Research, General interest, News, opinion and commentary, Otezla (Medication)
Abstract

Summit:Celgene Corporation.has issued the following press release: Celgene Corporation (NASDAQ: CELG) today announced findings from the ACTIVE phase 3b clinical trial of OTEZLA(r) (apremilast), the Company's oral, selective inhibitor of [...]

Published
2016

9. Data on Early Onset of Efficacy for Oral OTEZLA(r) (apremilast) in Active Psoriatic Arthritis Presented at American College of Rheumatology

Subjects
AbbVie Inc., Celgene Corp., Pharmaceutical industry, Psoriatic arthritis -- Research, General interest, News, opinion and commentary, Otezla (Medication)
Abstract

Illinois: AbbVie Inc. has issued the following news release Celgene Corporation (NASDAQ: CELG) today announced findings from the ACTIVE phase 3b clinical trial of OTEZLA(r) (apremilast), the Company's oral, selective [...]

Published
2016

10. Data on Early Onset of Efficacy for Oral OTEZLA(r) (apremilast) in Active Psoriatic Arthritis Presented at American College of Rheumatology

Subjects
Celgene Corp., Pharmaceutical industry, Psoriatic arthritis -- Research, General interest, News, opinion and commentary, Otezla (Medication)
Abstract

Summit:Celgene Corporation.has issued the following press release: Celgene Corporation (NASDAQ: CELG) today announced findings from the ACTIVE phase 3b clinical trial of OTEZLA(r) (apremilast), the Company's oral, selective inhibitor of [...]

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results